2025 Q4 -tulosraportti
Vain PDF
21 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 40 | - | - | ||
| 900 | - | - | ||
| 1 000 | - | - | ||
| 500 | - | - | ||
| 5 745 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sittenWHY CIRCIO CANNOT BE COMPARED TO ANYTHING ELSE ON THE STOCK EXCHANGE 🧬⚡ There's a lot of noise (and yapping) on the forum now from people who are annoyed by red days, price volatility, and that things "don't go in a straight line". Let's clear up the biggest misunderstanding about this case: Circio is not a normal A4 stock. What we are in here, is in practice a pure Venture Capital (VC) case that coincidentally is available on an open stock exchange for retail investors. What does that actually mean? Normally, platform companies in this phase – with exponential technology like circVec, international heavyweight collaborations (Acuitas) and massive R&D – are hidden away in closed PE or VC funds. Why? Because value creation in deep biotech is never linear. Traditional investors expect a stock to rise nicely and orderly by 2 % after a "good quarterly report". That's not how this game works. Biology doesn't care about trading graphs. In a VC case, it shakes. It goes sideways. The price is manipulated by traders looking for dimes. People lose patience and throw in the cards because they get bored. But when the repricing in such cases first comes, it doesn't happen gradually. It happens with a bang. • A breakthrough in the data. • A validation from Big Pharma. • A licensing agreement at a conference like ASGCT. When the substance hits the market, the price gaps up – and those who tried to be smart by trading in and out, are left on the platform. Bottom line: Either you understand the asymmetry and potential in owning a piece of a global gene therapy platform, or you should buy index funds. It is meaningless to spend time analyzing small, daily price movements when the company is preparing to turn the entire RNA industry upside down. Let traders yap about the noise. We focus on the substance. We know what we own. ♟️🧱🍷
·1 t sittenJust a thought, but if I don't buy warrants, wouldn't I still have bought CRNA cheaply when the warrants are exercised, because for example if the price is then at 10kr and everyone with warrants exercises at 8kr8will not the price automatically fall to around the 8 area due to all those trades at 8kr?
·1 t sittenThere is probably no doubt that the management hopes for full redemption of TR to further strengthen itself financially. Especially considering that the repair issue at 10:80 lapsed when the share price was down. There is probably also no doubt that it is in the company's best interest to raise as much capital as possible to stand on its own feet in further research and development, as well as to make itself more robust towards potential stakeholders. The question is who can afford to redeem TR. It must be assumed that the larger players have already positioned themselves, or plan to do so, and have their finances ready. As a «small shareholder», most are probably more price-sensitive and in the short term benefit from the lowest possible price to be able to exercise as many TR as possible. Even though the plan is set with dates and guidelines for implementation, the game is still unpredictable here and now. When the exercise price is set in a couple of weeks, we will know more. But, the joker remains unanswered, namely if and when, the management might release price-driving news that could affect an individual's financial ability to redeem TR.
·3 min sittenIt would greatly surprise me if the company does not provide all positive information they can give in the period 8th to 22nd May. This is to bring in a decent amount of TR money. There must be information that triggers buying interest above 10.80 for continued price increase. If this doesn't happen, my lottery ticket is that we fall to both 7 and 5 in the dip. Anything can happen here!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
21 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenWHY CIRCIO CANNOT BE COMPARED TO ANYTHING ELSE ON THE STOCK EXCHANGE 🧬⚡ There's a lot of noise (and yapping) on the forum now from people who are annoyed by red days, price volatility, and that things "don't go in a straight line". Let's clear up the biggest misunderstanding about this case: Circio is not a normal A4 stock. What we are in here, is in practice a pure Venture Capital (VC) case that coincidentally is available on an open stock exchange for retail investors. What does that actually mean? Normally, platform companies in this phase – with exponential technology like circVec, international heavyweight collaborations (Acuitas) and massive R&D – are hidden away in closed PE or VC funds. Why? Because value creation in deep biotech is never linear. Traditional investors expect a stock to rise nicely and orderly by 2 % after a "good quarterly report". That's not how this game works. Biology doesn't care about trading graphs. In a VC case, it shakes. It goes sideways. The price is manipulated by traders looking for dimes. People lose patience and throw in the cards because they get bored. But when the repricing in such cases first comes, it doesn't happen gradually. It happens with a bang. • A breakthrough in the data. • A validation from Big Pharma. • A licensing agreement at a conference like ASGCT. When the substance hits the market, the price gaps up – and those who tried to be smart by trading in and out, are left on the platform. Bottom line: Either you understand the asymmetry and potential in owning a piece of a global gene therapy platform, or you should buy index funds. It is meaningless to spend time analyzing small, daily price movements when the company is preparing to turn the entire RNA industry upside down. Let traders yap about the noise. We focus on the substance. We know what we own. ♟️🧱🍷
- ·1 t sittenJust a thought, but if I don't buy warrants, wouldn't I still have bought CRNA cheaply when the warrants are exercised, because for example if the price is then at 10kr and everyone with warrants exercises at 8kr8will not the price automatically fall to around the 8 area due to all those trades at 8kr?
- ·1 t sittenThere is probably no doubt that the management hopes for full redemption of TR to further strengthen itself financially. Especially considering that the repair issue at 10:80 lapsed when the share price was down. There is probably also no doubt that it is in the company's best interest to raise as much capital as possible to stand on its own feet in further research and development, as well as to make itself more robust towards potential stakeholders. The question is who can afford to redeem TR. It must be assumed that the larger players have already positioned themselves, or plan to do so, and have their finances ready. As a «small shareholder», most are probably more price-sensitive and in the short term benefit from the lowest possible price to be able to exercise as many TR as possible. Even though the plan is set with dates and guidelines for implementation, the game is still unpredictable here and now. When the exercise price is set in a couple of weeks, we will know more. But, the joker remains unanswered, namely if and when, the management might release price-driving news that could affect an individual's financial ability to redeem TR.·3 min sittenIt would greatly surprise me if the company does not provide all positive information they can give in the period 8th to 22nd May. This is to bring in a decent amount of TR money. There must be information that triggers buying interest above 10.80 for continued price increase. If this doesn't happen, my lottery ticket is that we fall to both 7 and 5 in the dip. Anything can happen here!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 40 | - | - | ||
| 900 | - | - | ||
| 1 000 | - | - | ||
| 500 | - | - | ||
| 5 745 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
21 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenWHY CIRCIO CANNOT BE COMPARED TO ANYTHING ELSE ON THE STOCK EXCHANGE 🧬⚡ There's a lot of noise (and yapping) on the forum now from people who are annoyed by red days, price volatility, and that things "don't go in a straight line". Let's clear up the biggest misunderstanding about this case: Circio is not a normal A4 stock. What we are in here, is in practice a pure Venture Capital (VC) case that coincidentally is available on an open stock exchange for retail investors. What does that actually mean? Normally, platform companies in this phase – with exponential technology like circVec, international heavyweight collaborations (Acuitas) and massive R&D – are hidden away in closed PE or VC funds. Why? Because value creation in deep biotech is never linear. Traditional investors expect a stock to rise nicely and orderly by 2 % after a "good quarterly report". That's not how this game works. Biology doesn't care about trading graphs. In a VC case, it shakes. It goes sideways. The price is manipulated by traders looking for dimes. People lose patience and throw in the cards because they get bored. But when the repricing in such cases first comes, it doesn't happen gradually. It happens with a bang. • A breakthrough in the data. • A validation from Big Pharma. • A licensing agreement at a conference like ASGCT. When the substance hits the market, the price gaps up – and those who tried to be smart by trading in and out, are left on the platform. Bottom line: Either you understand the asymmetry and potential in owning a piece of a global gene therapy platform, or you should buy index funds. It is meaningless to spend time analyzing small, daily price movements when the company is preparing to turn the entire RNA industry upside down. Let traders yap about the noise. We focus on the substance. We know what we own. ♟️🧱🍷
- ·1 t sittenJust a thought, but if I don't buy warrants, wouldn't I still have bought CRNA cheaply when the warrants are exercised, because for example if the price is then at 10kr and everyone with warrants exercises at 8kr8will not the price automatically fall to around the 8 area due to all those trades at 8kr?
- ·1 t sittenThere is probably no doubt that the management hopes for full redemption of TR to further strengthen itself financially. Especially considering that the repair issue at 10:80 lapsed when the share price was down. There is probably also no doubt that it is in the company's best interest to raise as much capital as possible to stand on its own feet in further research and development, as well as to make itself more robust towards potential stakeholders. The question is who can afford to redeem TR. It must be assumed that the larger players have already positioned themselves, or plan to do so, and have their finances ready. As a «small shareholder», most are probably more price-sensitive and in the short term benefit from the lowest possible price to be able to exercise as many TR as possible. Even though the plan is set with dates and guidelines for implementation, the game is still unpredictable here and now. When the exercise price is set in a couple of weeks, we will know more. But, the joker remains unanswered, namely if and when, the management might release price-driving news that could affect an individual's financial ability to redeem TR.·3 min sittenIt would greatly surprise me if the company does not provide all positive information they can give in the period 8th to 22nd May. This is to bring in a decent amount of TR money. There must be information that triggers buying interest above 10.80 for continued price increase. If this doesn't happen, my lottery ticket is that we fall to both 7 and 5 in the dip. Anything can happen here!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 40 | - | - | ||
| 900 | - | - | ||
| 1 000 | - | - | ||
| 500 | - | - | ||
| 5 745 | - | - |
Välittäjätilasto
Dataa ei löytynyt